

**COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**

NOTE: This special called meeting will be held virtually via Zoom webinar.

Thursday, November 18, 2021

1:00 P.M. to 4:00 P.M. (Eastern)

Access Information

Smartphone/Web	Dial-In
https://magellanhealth.zoom.us/j/96678131651 Webinar ID: 966 7813 1651 Password: 617843	+1 312 626 6799 (US Toll) OR +1 646 558 8656 (US Toll) Webinar ID: 966 7813 1651 Passcode: 617843

AGENDA

- I. Call to Order and Welcome**
- II. Executive Session (upon request)**
- III. Old Business**
 - a. Approval of Meeting Minutes
- IV. New Business**
 - a. New Products to Market to be reviewed as single products:
 - i. Brexafemme[®] (Antifungals: Oral)
 - ii. Kerendia[®] (Non-PDL drug class)
 - iii. Verquvo[®] (Non-PDL drug class)
- I. Therapeutic Classes with Recommended Changes**
 - a. Hypoglycemics, Incretin Mimetics/Enhancers
 - i. Diabetes: DPP-4 Inhibitors
 - ii. Diabetes: GLP-1 Receptor Agonists
 - b. Pulmonary Arterial Hypertension (PAH) Agents
 - c. Acne Agents, Topical
 - d. Antipsoriatics, Oral
 - e. Antipsoriatics, Topical
 - f. Steroids, Topical
 - g. Cytokine and CAM Antagonists (Immunomodulators)
 - h. Ophthalmics, Glaucoma Agents
 - i. Ophthalmic Beta Blockers
 - ii. Ophthalmic Carbonic Anhydrase Inhibitors
 - iii. Ophthalmic Combinations for Glaucoma
 - iv. Ophthalmic Prostaglandin Agonists
 - v. Ophthalmic Sympathomimetics
 - vi. Ophthalmics, Glaucoma Agents (Other)
- V. Consent Agenda**

- a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

<ul style="list-style-type: none"> • Acne Agents, Oral • Antibiotics, Topical • Antifungals, Topical • Antiparasitics, Topical • Antivirals, Topical • Rosacea Agents, Topical • Antiemetics & Antivertigo Agents <ul style="list-style-type: none"> ○ Anti-Emetics: Other ○ Oral Anti-Emetics: 5-HT3 Antagonists ○ Oral Anti-Emetics: NK-1 Antagonists ○ Oral Anti-Emetics: Δ-9-THC Derivatives • Antispasmodics/Anticholinergics • Antidiarrheals • Anti-Ulcer Protectants • Bile Salts • GI Motility Agents • <i>H. pylori</i> Treatment • Histamine II Receptor Blockers <ul style="list-style-type: none"> ○ H2Receptor Antagonists • Laxatives and Cathartics • Proton Pump Inhibitors • Ulcerative Colitis Agents 	<ul style="list-style-type: none"> • Immunomodulators, Atopic Dermatitis • Immunosuppressives, Oral <ul style="list-style-type: none"> ○ Immunosuppressants • Multiple Sclerosis Agents • Spinal Muscular Atrophy • Ophthalmics, Allergic Conjunctivitis <ul style="list-style-type: none"> ○ Ophthalmic Antihistamines ○ Ophthalmic Mast Cells Stabilizers • Ophthalmics, Anti-inflammatories <ul style="list-style-type: none"> ○ Ophthalmic NSAIDs ○ Ophthalmic Anti-inflammatory Steroids • Ophthalmics, Antibiotics-Steroid Combinations • Ophthalmics, Antibiotics <ul style="list-style-type: none"> ○ Ophthalmic Quinolones ○ Ophthalmic Antibiotics, Non-Quinolones • Ophthalmics, Antivirals • Ophthalmic Immunomodulators • Ophthalmics, Mydriatics & Mydriatic Combinations • Ophthalmic Vasoconstrictors • Otic Antibiotics • Otics, Anti-Inflammatories <ul style="list-style-type: none"> ○ Otic Anesthetics and Anti-Inflammatories
--	--

V. Adjournment

- a. Schedule of Upcoming Meetings
- i. **January 20, 2022**
 - ii. **March 17, 2022**
 - iii. **May 19, 2022**
 - iv. **July 21, 2022**

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria please go to <https://kyportal.magellanmedicaid.com/provider/public/home.xhtml>.

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at: <https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.